Email this article CONSTRUCTION OF RECOMBINANT ATTENUATED BORDETELLA PERTUSSIS BACTERIA OF PTXP3 GENOTYPE
- Authors: Semin E.G.1, Sinyashina L.N.1, Medkova A.Y.1, Karataev G.I.1
-
Affiliations:
- Gamaleya National Research Centre of Epidemiology and Microbiology
- Issue: Vol 95, No 4 (2018)
- Pages: 33-41
- Section: СИМБИОТИЧЕСКИЕ ВЗАИМОДЕЙСТВИЯ НОРМОФЛОРЫ И ХОЗЯИНА
- Submitted: 10.04.2019
- Published: 28.08.2018
- URL: https://microbiol.crie.ru/jour/article/view/284
- DOI: https://doi.org/10.36233/0372-9311-2018-4-33-41
- ID: 284
Cite item
Full Text
Abstract
Aim. The construction of recombinant attenuated Bordetella pertussis bacteria of ptxP3 genotype and its genetic and biological stability characteristics. Materials and methods. During construction of recombinant attenuated bacteria of ptxP3 genotype virulent Bordetella pertussis bacteria of ptxP1 genotype were used as a recipient. PtxP1 genotype bacteria are used for whole cell pertussis (wP) vaccine production in Russia. Mutant bacteria B. pertussis 475 were received by crossing-over between chromosome comprising native copy of target sequence and its mutant copy in recombinant suicide plasmid transferred in recipient bacteria by conjugation. Genetically engineered construction of recombinant plasmids was conducted. The structure of modified chromosome locus of attenuated bacteria was determined by PCR and amplification fragments sequence. The stability of structure and characteristics of attenuated bacteria was defined after 15 passages of strains on culture medium and 5 passages in mice. Results. Isogenic attenuated ptxP1 B. pertussis 4M and ptxP3 B. pertussis 4MKS were constructed. These bacteria produce non-toxic pertussis toxin (PT) and do not produce dermonecrotic toxin (DNT). The promoter region of ptx operon contains mutation, typical for «new» genotype of circulating virulent bacteria and increasing PT production. The structure of modified DNA fragments and characteristics of attenuated bacteria did not change while storing and after passages on culture medium and in mice. Conclusion. Recombinant attenuated bacteria B. pertussis 4MKS of «new» ptxP3 genotype are constructed. Application perspectiveness of genetically engineered modification of isogenic B.pertussis bacteria for pertussis vaccines development is shown.
About the authors
E. G. Semin
Gamaleya National Research Centre of Epidemiology and Microbiology
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
L. N. Sinyashina
Gamaleya National Research Centre of Epidemiology and Microbiology
Email: noemail@neicon.ru
Russian Federation
A. Yu. Medkova
Gamaleya National Research Centre of Epidemiology and Microbiology
Email: noemail@neicon.ru
Russian Federation
G. I. Karataev
Gamaleya National Research Centre of Epidemiology and Microbiology
Email: noemail@neicon.ru
Russian Federation
References
- Алексеева И.А., Чупринина Р.П., Борисова В.Н. Сравнительный анализ безопасности и эффективности отечественных и зарубежных комплексных вакцин, содержащих цельноклеточную коклюшную вакцину. Эпидемиология и вакцинопрофилактика. 2012, 3(64): 48-54.
- Борисова О.Ю., Пименова А.С., Попова О.П. и др. Структура популяции штаммов возбудителя коклюша на территории России. Эпидемиология и вакцинопрофилактика. 2016, 4(86): 22-27.
- Захарова М.С. Влияние вакцинации на эпидемиологию коклюша в СССР. В кн.: Эпидемиология и иммунопрофилактика коклюша в СССР, ВНР, НРБ и ЧССР. М., 1985.
- Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование. М., Мир, 1984.
- МУК 4.2.2317-08. Методические указания. Издание официальное. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. М., 2009.
- Перелыгина О. В., Алексеева И. А. Безопасность комбинированных вакцин с цельноклеточным коклюшным компонентом. Эпидемиология и вакцинопрофилактика. 2016, 6 (91): С. 62-69.
- Пименова А.С., Борисова О.Ю., Цвиркун О.В. и др. Эффективность применения молекулярно-генетической диагностики при обследовании очагов коклюшной инфекции. Журн. инфекция и иммунитет. 2017, 7(2): 162-170.
- Синяшина Л.Н., Синяшина Л.С., Семин Е.Г. и др. Конструирование генетически аттенуированных бактерий Bordetella pertussis, утративших активность дермонекротического токсина и продуцирующих измененную нетоксичную форму коклюшного токсина. Молекулярная генетика, микробиология и вирусология. 2010, 3: 31-36.
- Mielcarek N., Debrie A.S., Raze D. et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006, 2 (7): 65-69.
- Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect. Genet. Evol. 2010, 10 (1): 36-49.
- Sato Y, Sato H. Development of acellular pertussis vaccines. Biologicals. 1999, 27: 61-67.
- WHO. Expert committee on biological standardization. Recommendation to Assure the Quality, Sаfety and Efficacy of Acellular Pertussis Vaccines. Geneva, 17-20 October. 2011.
- WHO. Weekly epidemiological record. 2014, 89(21).
Supplementary files
